<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640272</url>
  </required_header>
  <id_info>
    <org_study_id>RBM 007-003</org_study_id>
    <nct_id>NCT04640272</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration</brief_title>
  <acronym>RAMEN</acronym>
  <official_title>A Multi-Center, Open Label, TOFU Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ribomic USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ribomic USA Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and&#xD;
      safety of additional intravitreal injections of RBM-007 in subjects with wet age-related&#xD;
      macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, non-comparative</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity - continuous</measure>
    <time_frame>Month 5</time_frame>
    <description>Mean change in Best Corrected Visual Acuity from Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity - categorical</measure>
    <time_frame>Month 5</time_frame>
    <description>Proportion of patients gaining more than 15 letters as measured by Best Corrected Visual Acuity from Baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Exudative Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>RBM-007 injectable solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBM-007</intervention_name>
    <description>Intravitreal injection</description>
    <arm_group_label>RBM-007 injectable solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide signed written informed consent on the Institutional Review Board (IRB)/Ethics&#xD;
             Committee (EC) approved Informed Consent Form (ICF) and provide authorization as&#xD;
             appropriate for local privacy regulations.&#xD;
&#xD;
          2. Male or female 55 years of age or older on the date of signing the ICF and able and&#xD;
             willing to comply with all treatment and study procedures.&#xD;
&#xD;
          3. Subjects must have completed all scheduled visits of previous study. Subjects can only&#xD;
             enter this study after exiting previous study&#xD;
&#xD;
          4. Subjects for which previous previous masked treatment arms with intravitreal&#xD;
             anti-vascular endothelial growth factor (anti-VEGF) agents EyleaÂ® and/or RBM-007 has&#xD;
             not demonstrated improvement in vision; subjects with less than 15 letter Best&#xD;
             Corrected Visual Acuity (BCVA) improvement in TOFU study at exit visit over its&#xD;
             baseline.&#xD;
&#xD;
          5. Diagnosis of exudative age-related macular degeneration (AMD) in the study eye, as&#xD;
             assessed by spectral domain optical coherence tomography (SD-OCT).&#xD;
&#xD;
          6. Absence of central atrophy or retinal epithelial tear in the fovea or any condition&#xD;
             preventing VA improvement in the study eye.&#xD;
&#xD;
          7. BCVA of 24 ETDRS letters (20/320) or better in the fellow eye.&#xD;
&#xD;
          8. Reasonably clear media and some fixation in the study eye to allow for good quality&#xD;
             SD-OCT and fundus photography.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subjects whose vision have improved &gt;15 BCVA letters at exit visit of previous&#xD;
             study over its baseline 2. Subjects who experienced any drug related serious adverse&#xD;
             event during previous study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Padma Bezwada, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ribomic USA Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Research Institute, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Medical Consultants Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, M.D., P.C.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

